Bioharvest Sciences Inc 6-K, filed Nov 8, 2024
Bioharvest Sciences Inc. (BHST)
About this 6-K
Bioharvest Sciences Inc filed this 6-K on November 8, 2024.
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of November 2024
Commission file number: 000-56663
BIOHARVEST SCIENCES INC.
(Exact name of Registrant as specified in its charter)
Not applicable
(Translation of Registrant’s name into English)
1140-625 Howe Street, Vancouver, British Columbia V6C 2T6, Canada
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
☒ Form 20-F ☐ Form 40-F
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
|
Exhibits:
Exhibit | Description |
News Release dated November 7, 2024 | |
Material Change Report dated November 7, 2024 |
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| BIOHARVEST SCIENCES INC. |
| (Registrant) |
|
|
Date: November 8, 2024 | /s/ David Ryan |
| Name: David Ryan |
| Title: Vice-President, Investor Relations, & Secretary |
BioHarvest Sciences Announces Uplisting to the Nasdaq Global Market
Common Shares to Begin Trading on Nasdaq on Tuesday, November 12, 2024
Vancouver, British Columbia and Rehovot, Israel – November 7, 2024 – BioHarvest Sciences Inc. (“BioHarvest” or the “Company”) (CSE: BHSC) (OTCQB: CNVCF), a company pioneering its patented Botanical Synthesis technology platform, today announced that the Nasdaq Stock Market LLC has approved the listing of the Company’s common shares on the Nasdaq Global Market (“Nasdaq”).
The Company expects to begin trading on the Nasdaq on Tuesday, November 12th, 2024, under the new symbol “BHST”. The company’s common shares will trade on the OTCQB until market close on November 11th, 2024, and will continue to trade on the Canadian Securities Exchange (“CSE”).
Dr. Zaki Rakib, Chairman of BioHarvest Sciences, said: “We are pleased to announce the listing of our shares on the Nasdaq, representing a significant capital markets milestone for BioHarvest Sciences and our valued shareholder partners. We believe this listing will serve to expand our potential shareholder base, improve liquidity and elevate our public profile in the industry – ultimately helping to enhance long-term shareholder value creation.”
Ilan Sobel, Chief Executive Officer of BioHarvest Sciences, concluded: “I am incredibly proud of the efforts of the whole team at BioHarvest, whose operational execution has positioned us to list on a senior U.S. exchange and tap into a global shareholder base. We look forward to our first day of trading on the Nasdaq on Tuesday, November 12, 2024. I would like to thank our valued shareholder partners, whose significant support has played an important role in our continued success.”
About BioHarvest Sciences Inc.
BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) (FSE: 8MV) is a leader in Botanical Synthesis, leveraging its patented technology platform to grow the active ingredients in plants, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and production organization (CDMO) on behalf of customers seeking complex molecules, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. To learn more, please visit www.bioharvest.com.
Forward-Looking Statements
Information set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. There is no assurance of additional future contracts. Readers are cautioned that future contracts or increased revenue is not necessarily an increase in net income or profitability as costs will likely increase as well. All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.
Neither the Canadian Securities Exchange nor its Regulation Services Provider accept responsibility for the adequacy or accuracy of this release.
This release has been reviewed and approved by Dave Ryan, VP Investor Relations, who accepts responsibility for its contents.
BioHarvest Corporate Contact:
Dave Ryan, VP Investor Relations & Director
(604) 622-1186
info@bioharvest.com
Investor Relations Contact:
Lucas A. Zimmerman
Managing Director
MZ Group - MZ North America
(949) 259-4987
BHSC@mzgroup.us
FORM 51-102F3
MATERIAL CHANGE REPORT
Item 1.Name and Address of Company
BIOHARVEST SCIENCES INC.
Suite 1140 – 625 Howe Street
Vancouver, BC, V6C 2T6
(the “Company”)
Item 2.Date of Material Change
November 7, 2024
Item 3.News Release
The news release (the “News Release”) was issued and disseminated by Newsfile Corp. on November 7, 2024.
Item 4.Summary of Material Change
The Company announced that the Nasdaq Stock Market LLC approved the listing of the common shares of the Company (the “Common Shares”) on the Nasdaq Global Market. The Company expects trading of the Common Shares on the Nasdaq Global Market to begin on November 12, 2024.
Item 5.Full Description of Material Change
See the News Release attached hereto as Schedule “A”.
Item 6.Reliance on Subsection 7.1(2) of National Instrument 51-102
Not applicable.
Item 7.Omitted Information
None.
Item 8.Executive Officer
For further information, please contact:
David Ryan
Secretary and VP, Investor Relations
604 622-1187
Item 9.Date of Report
November 7, 2024
SCHEDULE “A”
NEWS RELEASE
(See attached)
BioHarvest Sciences Announces Uplisting to the Nasdaq Global Market
Common Shares to Begin Trading on Nasdaq on Tuesday, November 12, 2024
Vancouver, British Columbia and Rehovot, Israel – November 7, 2024 – BioHarvest Sciences Inc. (“BioHarvest” or the “Company”) (CSE: BHSC) (OTCQB: CNVCF), a company pioneering its patented Botanical Synthesis technology platform, today announced that the Nasdaq Stock Market LLC has approved the listing of the Company’s common shares on the Nasdaq Global Market (“Nasdaq”).
The Company expects to begin trading on the Nasdaq on Tuesday, November 12th, 2024, under the new symbol “BHST”. The company’s common shares will trade on the OTCQB until market close on November 11th, 2024, and will continue to trade on the Canadian Securities Exchange (“CSE”).
Dr. Zaki Rakib, Chairman of BioHarvest Sciences, said: “We are pleased to announce the listing of our shares on the Nasdaq, representing a significant capital markets milestone for BioHarvest Sciences and our valued shareholder partners. We believe this listing will serve to expand our potential shareholder base, improve liquidity and elevate our public profile in the industry – ultimately helping to enhance long-term shareholder value creation.”
Ilan Sobel, Chief Executive Officer of BioHarvest Sciences, concluded: “I am incredibly proud of the efforts of the whole team at BioHarvest, whose operational execution has positioned us to list on a senior U.S. exchange and tap into a global shareholder base. We look forward to our first day of trading on the Nasdaq on Tuesday, November 12, 2024. I would like to thank our valued shareholder partners, whose significant support has played an important role in our continued success.”
About BioHarvest Sciences Inc.
BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) (FSE: 8MV) is a leader in Botanical Synthesis, leveraging its patented technology platform to grow the active ingredients in plants, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and production organization (CDMO) on behalf of customers seeking complex molecules, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. To learn more, please visit www.bioharvest.com.
Forward-Looking Statements
Information set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. There is no assurance of additional future contracts. Readers are cautioned that future contracts or increased revenue is not necessarily an increase in net income or profitability as costs will likely increase as well. All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.
Neither the Canadian Securities Exchange nor its Regulation Services Provider accept responsibility for the adequacy or accuracy of this release.
This release has been reviewed and approved by Dave Ryan, VP Investor Relations, who accepts responsibility for its contents.
BioHarvest Corporate Contact:
Dave Ryan, VP Investor Relations & Director
(604) 622-1186
info@bioharvest.com
Investor Relations Contact:
Lucas A. Zimmerman
Managing Director
MZ Group - MZ North America
(949) 259-4987
BHSC@mzgroup.us